KR950000149A - 오메프라졸 주사용 제제 - Google Patents

오메프라졸 주사용 제제 Download PDF

Info

Publication number
KR950000149A
KR950000149A KR1019930009791A KR930009791A KR950000149A KR 950000149 A KR950000149 A KR 950000149A KR 1019930009791 A KR1019930009791 A KR 1019930009791A KR 930009791 A KR930009791 A KR 930009791A KR 950000149 A KR950000149 A KR 950000149A
Authority
KR
South Korea
Prior art keywords
omeprazole
buffer
methylglucamine
injection
present
Prior art date
Application number
KR1019930009791A
Other languages
English (en)
Other versions
KR960008233B1 (ko
Inventor
김상호
남미순
김현진
류길수
Original Assignee
하기주
주식회사 코오롱
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하기주, 주식회사 코오롱 filed Critical 하기주
Priority to KR1019930009791A priority Critical patent/KR960008233B1/ko
Publication of KR950000149A publication Critical patent/KR950000149A/ko
Application granted granted Critical
Publication of KR960008233B1 publication Critical patent/KR960008233B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 오메프라졸 및 그의 염의 안정화된 수성 주사용 제제에 관한 것이다.
본 발명은, 오메프라졸 또는 비경구투여 가능한 그의 염을 약물로서 함유하는 용액의 pH를 N-메틸글루카민 또는 완충액계로서 2-아미노-2-하이드록시메틸-1,3-프로판디올 완충용액, 또는 N-메틸글루카민+포타슘 하이드로겐포스페이트 완충액 등을 사용하여 pH 8.5-9.5의 범위로 조절하는 제조하는 것을 특징으로 하는 안정화된 오메프라졸의 주사용 제제를 제공한다.
본 발명에 의한 오메프라졸의 주사용 약제는 활성성분의 안정화 효과가 매우 뛰어난 오메프라졸의 주사용 약제이다.

Description

오메프라졸 주사용 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. 약물로서 오메프라졸 또는 비경구투여 가능한 오메프라졸 염, 및 제약학적으로 혀용되는 통상의 주사용 첨가제를 주사용 증류수에 용해시키고, 이 용액을 N-메틸글루카민 또는 완충용액으로 pH 8.5-9.5로 조절하여 통상의 방법으로 주사제용 용기에 충전한 오메프라졸 및 그 염의 주사용 제제.
  2. 제1항에 있어서, 완충용액이 2-아미노-2-하이드록시메틸-1,3-프로판디올 완충용액, 또는 N-메틸글루카민+포타슘 하이드로겐포스페이트 완충용액임을 특징으로 하는 오메프라졸 및 그 염의 주사용 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930009791A 1993-06-01 1993-06-01 오메프라졸 주사용 제제 KR960008233B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019930009791A KR960008233B1 (ko) 1993-06-01 1993-06-01 오메프라졸 주사용 제제

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930009791A KR960008233B1 (ko) 1993-06-01 1993-06-01 오메프라졸 주사용 제제

Publications (2)

Publication Number Publication Date
KR950000149A true KR950000149A (ko) 1995-01-03
KR960008233B1 KR960008233B1 (ko) 1996-06-21

Family

ID=19356585

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930009791A KR960008233B1 (ko) 1993-06-01 1993-06-01 오메프라졸 주사용 제제

Country Status (1)

Country Link
KR (1) KR960008233B1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114159396A (zh) * 2021-10-21 2022-03-11 济南同路医药科技发展有限公司 一种注射用艾司奥美拉唑钠冻干制剂及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100900647B1 (ko) * 2008-01-31 2009-06-02 김기호 이중냉각구조의 다면균일 순환급속 냉각장치

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114159396A (zh) * 2021-10-21 2022-03-11 济南同路医药科技发展有限公司 一种注射用艾司奥美拉唑钠冻干制剂及其制备方法

Also Published As

Publication number Publication date
KR960008233B1 (ko) 1996-06-21

Similar Documents

Publication Publication Date Title
KR890015745A (ko) 수용액으로 존재하는 피록시캄의 제약 조성물 및 그의 제조방법
BR9510452A (pt) Composição farmacêutica e aquosa estéril para a administração parenteral processos para limitar o potencial de crescimento microbiano em composição farmacêutica estéril para a administração parenteral para produzir anestesia em um animal de sangue quente e para aperfeiçoar o tempo de administração e/ou o tempo entre as trocas de conjuntos
EP0217645A3 (en) Stable formulation of biologically active proteins for parenteral injection
KR940008681A (ko) 디클로페낙 염용 비경구 용액
DE69840106D1 (de) Formulierungen für amylin peptidagonisten mit insulin
KR970061270A (ko) 히토성장호르몬을 함유하는 의약제제
KR940703689A (ko) 성장호르몬과 아스파라진으로 이루어지는 안정화된 약학제제(a stabil-ized pharmaceutical formulation comprising growth gormone and asparagine)
MX173607B (es) Antitranspirante cristalino y metodo para su preparacion
RU94046143A (ru) Фармацевтическая композиция для лечения глаукомы
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
KR920007571A (ko) 영양학적 조성물 및 이의 제조방법
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
KR880007060A (ko) 제약 조성물
KR890006644A (ko) 결정성 β-락탐 수화물
KR900006330A (ko) 피롤로[3,2-e]피라졸로[1,5-a]피리미딘 유도체 및 이를 함유하는 약제
JPS6416724A (en) Stable and injectable vinca dimer salt solution
FR2380782A1 (fr) Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer
KR950000149A (ko) 오메프라졸 주사용 제제
CA2244389A1 (en) Cilansetron pharmaceutical preparation stabilized against racemization
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
FI943103A (fi) Puolikiinteä farmaseuttinen aine ja menetelmä sen valmistamiseksi
KR890000009A (ko) 농업용 생리활성제
KR930023338A (ko) 데포우 제제
KR890015741A (ko) 상승작용을 갖는 수의학적 조성물 및 그의 제조방법
KR890012960A (ko) 결정성 β-락탐 용매화물

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
O035 Opposition [patent]: request for opposition
SUBM Submission of document of abandonment before or after decision of registration